Where does OncoResponse's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across OncoResponse's 2 recorded funding rounds.

Premier Alternatives

OncoResponse

Houston, TX · Founded 2015 · Privately Held (backing)

Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. OncoResponse is based in Houston, TX and was founded in 2015. Its last reported valuation was $36 million in May 2023. It has raised $180 million across 2 recorded rounds; the latest was a $6 million early-stage round in Apr 2025.

Last reported valuation

$36.0M

Oct 2026

Priced at

—

Total raised

$180.0M

Last round

Early Stage VC

Apr 2025

Cap table — not yet on record

OncoResponse's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of OncoResponse with a free account

·The complete investor list: 25 names
·Watch OncoResponse: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about OncoResponse

Where does OncoResponse's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across OncoResponse's 2 recorded funding rounds.